Advertisement


Paula Aristizabal, MD, MAS, on Surviving Childhood Leukemia Near the Border of the United States and Mexico

2023 ASCO Annual Meeting

Advertisement

Paula Aristizabal, MD, MAS, of the University of California, San Diego, and Rady Children’s Hospital, talks about using a health systems strengthening approach to improve leukemia care and survival in a public Mexican hospital in the region of the border between the United States and Mexico. The demonstrated increase in overall survival across a decade after implementation of the program seems to validate the use of such models, not only to improve clinical outcomes, but also to build sustainable hospital capacity, financially and organizationally (Abstract 1502).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Paula Aristizabal, MD: Acute lymphoblastic leukemia is the most common childhood cancer and survival has improved dramatically in high income countries to rates over 80%. Unfortunately, in low and middle income countries, survival has not increased at the same pace. For example, in Mexico, a low income country that is just across the border from the US, survival range is between 10% and 60%. Since in San Diego we share a border with Tijuana, we saw the disparities and we thought that it was our social responsibility to do something about it so we implemented a twinning program and twinning involves when a center of excellence in a high income country partners and collaborates with a center in a low, middle income country. We started this twinning program in 2008 in collaboration with St. Jude Children's Research Hospital, and we were able to implement a new team in Tijuana that was able to provide the best care possible for all the pediatric cancers. Then in 2013, we realized that the burden of leukemia was getting higher and higher and we decided to implement a new model of health system strengthening called the WHO Framework for Action. The WHO Framework for Action has six building blocks that provide all the elements to improve care in a health system. We incorporated the WHO Framework for Action into the already existing twinning model to improve leukemia survival. We provided training to the team in Tijuana. We provided protocols that they could adapt. We provided mentorship and we provided support for a new infrastructure to develop the best possible leukemia care for children with with leukemia in Baja, California, Mexico. After the implementation of the program, survival for leukemia improved from 59% to 65% and, importantly, the survival for standard risk leukemia improved from 73% before implementing the program to 100%, which is totally amazing because that is the same survival that we have in San Diego, just 20 miles from Tijuana. Survival for high risk leukemia improved from 48% to 55%. It wasn't so significant but we know that that is an area of improvement that we hope that we can tackle in our next steps of the program. Our model in Tijuana, combining a twinning program with the WHO Framework for Action, was effective in improving survival in a low and middle income country. This model can be applicable to a partnership between a high income country and a low, middle income country, especially in regions that share a border but also in other low and middle income countries remotely. Something that we learned from COVID is that you can apply many of these models working remotely and we are extremely pleased with these results. Our next steps include the improvement of the survival for patients with high risk leukemia.

Related Videos

Gynecologic Cancers
Immunotherapy

Bradley J. Monk, MD, on Cervical Cancer: Findings on Pembrolizumab Plus Chemotherapy

Bradley J. Monk, MD, of the University of Arizona, Phoenix, and Creighton University, discusses phase III findings from the KEYNOTE-826 study of overall survival results in patients with persistent, recurrent, or metastatic cervical cancer. Study participants received first-line treatment of pembrolizumab plus chemotherapy, with or without bevacizumab, which reduced the risk of death by up to 40% in three different subsets of patients (Abstract 5500).

Bladder Cancer
Immunotherapy

Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab

Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to demonstrate promising survival trends with rapid and durable responses in this population (Abstract 4505).

Lymphoma

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on DLBCL: New Data on ctDNA Status and Clinical Outcomes

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss findings from the POLARIX study, which provided the largest prospectively collected circulating tumor DNA (ctDNA) data set on patients with previously untreated diffuse large B-cell lymphoma. Achieving ctDNA-negative status was associated with improved outcomes when patients were treated with polatuzumab vedotin-piiq plus combination chemotherapy vs combination chemotherapy alone (Abstract 7523).

Gynecologic Cancers

Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Mansoor R. Mirza, MD, of Denmark’s Rigshospitalet and Copenhagen University Hospital, discuss new findings on dostarlimab-gxly plus carboplatin/paclitaxel, which improved progression-free survival while maintaining health-related quality of life, further supporting its use as a standard of care in primary advanced or recurrent endometrial cancer (Abstract 5504).

Kidney Cancer
Immunotherapy

Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib

Rana R. McKay, MD, of the University of California, San Diego, and Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center, discuss the 5-year follow-up results with the combination of a checkpoint inhibitor plus a VEGFR tyrosine kinase inhibitor as first-line treatment for patients with advanced clear cell renal cell carcinoma (RCC). Pembrolizumab plus axitinib continued to demonstrate improved survival outcomes as well as overall response rate vs sunitinib for patients with previously untreated disease (Abstract LBA4501).

Advertisement

Advertisement




Advertisement